8-K: Invivyd Launches PEMGARDA, Projects $150M-$200M in 2024 Revenue

Invivyd's PEMGARDA is now commercially available in the U.S., with the company projecting net product revenue between $150 million and $200 million for 2024.

Summary

• Invivyd has launched PEMGARDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised individuals in the U.S.
• The company anticipates net product revenue for PEMGARDA to be between $150 million and $200 million in 2024.
• Invivyd expects to end 2024 with at least $55 million in cash and cash equivalents.
• PEMGARDA received Emergency Use Authorization (EUA) from the FDA on March 22, 2024.
• The product is available for order through a network of authorized specialty distributors.
• A conference call was held on April 4, 2024, to discuss the launch progress.
• The wholesale acquisition cost (WAC) for PEMGARDA is $5,775.
• The company plans to share launch metrics, including patient lives covered by CMS and commercial payors, and the number of accounts ordering the product.
• Invivyd expects to begin reporting PEMGARDA net product revenue and associated COGS in the Q2 2024 earnings update.
• The company has been capitalizing inventory costs since March 2024, which will impact initial gross margins.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful launch of PEMGARDA, the revenue guidance, and the projected cash balance. However, there are some risks and uncertainties associated with the product's commercialization and regulatory environment.

Positives

• PEMGARDA is now commercially available in the U.S. less than two weeks after receiving EUA.
• The company has provided a net product revenue guidance of $150 million to $200 million for 2024.
• Invivyd anticipates ending 2024 with at least $55 million in cash and cash equivalents.
• The company has a clear commercial strategy with defined phases for product availability, reimbursement, and access.
• Invivyd plans to share launch metrics to provide visibility into their progress.

Negatives

• The emergency use of PEMGARDA is only authorized for the duration of the COVID-19 pandemic emergency declaration.
• Initial gross margins will be anomalous due to the capitalization of inventory costs starting in March 2024.
• There are limitations of the data supporting the benefits of PEMGARDA, as the evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and variants.
• Anaphylaxis has been observed with PEMGARDA, and the product has a boxed warning for anaphylaxis.

Risks

• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company's ability to successfully commercialize PEMGARDA depends on building and maintaining sales, marketing, and distribution capabilities.
• There are risks associated with competition, regulatory changes, and unexpected safety or efficacy data.
• The company relies on third parties for manufacturing, labeling, packaging, storing, and distributing PEMGARDA.
• The company's ability to achieve the projected revenue and cash balance depends on market demand and reimbursement coverage.
• The company's ability to continue as a going concern is dependent on securing adequate funding.

Future Outlook

Invivyd anticipates continued optimization of operational expenses and plans to share launch metrics to provide visibility into their progress. The company expects to begin reporting PEMGARDA net product revenue and associated COGS in the Q2 2024 earnings update.

Management Comments

• Dave Hering, Chief Executive Officer, stated that PEMGARDA is now commercially available for order across the U.S. less than two weeks after receiving EUA.
• Dave Hering noted this is a remarkable achievement for the organization and for the immunocompromised individuals they serve.

Industry Context

This announcement is significant as it marks the commercial launch of a new monoclonal antibody for COVID-19 prevention in a specific high-risk population. It highlights the ongoing need for preventative measures against COVID-19, particularly for those with compromised immune systems. The launch also demonstrates the continued innovation in the biopharmaceutical industry to address evolving viral threats.

Comparison to Industry Standards

• The projected revenue of $150M-$200M for the first year of PEMGARDA is a strong start for a new product in the monoclonal antibody space, but will need to be compared to other similar products as they are released.
• The company's expectation to end the year with at least $55M in cash is a positive sign of financial stability, but will need to be compared to other companies in the same stage of development.
• The wholesale acquisition cost (WAC) of $5,775 for PEMGARDA is in line with other monoclonal antibody therapies, but the actual net price will depend on payer negotiations and rebates.
• The company's plan to share launch metrics is a positive step towards transparency and will allow investors to track the progress of the launch against industry benchmarks.

Stakeholder Impact

• Shareholders will be impacted by the revenue guidance and the company's financial performance.
• Healthcare professionals will have a new option for pre-exposure prophylaxis of COVID-19 for their immunocompromised patients.
• Patients with moderate-to-severe immune compromise will have access to a new preventative treatment option.
• Suppliers and distributors will be involved in the manufacturing and distribution of PEMGARDA.

Next Steps

• Invivyd will continue to optimize operational expenses.
• The company will share launch metrics to provide visibility into their progress.
• Invivyd will begin reporting PEMGARDA net product revenue and associated COGS in the Q2 2024 earnings update.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibody, EUA, pre-exposure prophylaxis, Invivyd, revenue guidance, immunocompromised, commercial launch, net product revenue